This book provides a comprehensive resource for neuro-drug discovery and molecular targets for schizophrenia, from current therapies to evolving targets. The coverage begins with a discussion of prevalence and etiology, and an introduction to current therapies (which treat only certain, "positive" symptoms), as well as the rise of interest in addressing untreated symptoms. Subsequent sections focus on each major mechanistic hypothesis, beginning with a chapter that serves as an introduction and overview. Within these models, chapters focus on each major pharmacological target and address both the neurobiological and chemical aspects of that target.
Preface vii Contributors xi Introduction 1 Alan J. Cross 1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5 Aurelija Jucaite and Svante Nyberg 2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37 Philip G. Strange 3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51 Kevin N. Boyd and Richard B. Mailman 4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85 Judith A. Siuciak and William J. Pitts 5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115 Joseph T. Coyle, Alo Basu, and Michael Benneyworth 6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143 Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn 7 AMPA Receptor Positive Modulators 187 John A. Morrow, John K.F. Maclean, and Craig Jamieson 8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233 Jeffrey S. Albert and Michael W. Wood 9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255 Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones 10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273 Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis 11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295 Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic 12 alpha7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319 Mihaly Hajos and Bruce N. Rogers 13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355 Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu 14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381 Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson 15 GABA and Schizophrenia 425 John H. Kehne and George D. Maynard Index 469